Illumina Upgrades Custom Genotyping Offering to Suit Human Health, Ag-bio Market Needs
January 11, 2011
Illumina Upgrades Custom Genotyping Offering to Suit Human Health, Ag-bio Market Needs
Tristan Orpin, Illumina's chief commercial officer, said this week that the added flexibility of the iSelect custom genotyping offering will allow the firm to reach more customers doing human health and ag-bio research.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Custom Illumina Genotyping Arrays at Center of Ongoing iCOGS Consortium's Cancer Studies
April 2, 2013 / BioArray News - Aiming at '$12B Opportunity,' Illumina to Expand Sales Presence, Invest in Reproductive Health
May 14, 2013 / BioArray News - GenomeWeb Feature: New Techniques Driving Research into Epigenetic Changes in Cancer
April 16, 2013 / GenomeWeb Daily News - Survey Offers 'Cautious Array Forecast' for Illumina as Sequencing, Affymetrix Products Gain Ground
April 16, 2013 / BioArray News - Studies Point to Key Deletion Behind Rare Blood Group
April 8, 2013 / GenomeWeb Daily News